Top

Published in:

01-03-2020 | Acute Liver Failure | Case Report

An Unusual Case of Acute Liver Failure Caused by Adjuvant Oral Tegafur-Uracil with Folinate Therapy for Colon Cancer Patient: a Case Report

Authors: Masatsugu Hiraki, Toshiya Tanaka, Futa Koga, Akimasa Saito, Noriko Oza, Osamu Ikeda, Tatsuya Manabe, Atsushi Miyoshi, Kenji Kitahara, Seiji Sato, Hirokazu Noshiro

Published in: Journal of Gastrointestinal Cancer | Issue 1/2020

Excerpt

Drug-induced liver injury (DILI) is one of the most common causes of liver disorder [1] and is defined as injury of the liver caused by the administration of drugs, including supplements, health foods, and traditional Chinese medicines [2, 3]. The chemotherapeutic reagents tegafur-uracil and folinate have been widely used in Japan as postoperative chemotherapy for colorectal cancer [4]. This therapy is known to have liver toxicity and may cause liver injury in a small proportion of patients [5‐7]. …

Zimmerman HJ. Drug-induced liver disease. Clin Liver Dis. 2000;4:73–96 vi.CrossRef

Leise MD, Poterucha JJ, Talwalkar JA. Drug-induced liver injury. Mayo Clin Proc. 2014;89:95–106.CrossRef

Takikawa H, Murata Y, Horiike N, Fukui H, Onji M. Drug-induced liver injury in Japan: an analysis of 1676 cases between 1997 and 2006. Hepatol Res. 2009;39:427–31.CrossRef

Watanabe T, Muro K, Ajioka Y, Hashiguchi Y, Ito Y, Saito Y, et al. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer. Int J Clin Oncol. 2018;23:1–34.CrossRef

Tashiro J, Yamaguchi S, Ishii T, Kondo H, Hara K, Shimizu H, et al. Oncologic outcomes of oral adjuvant chemotherapy regimens in stage III colon cancer: tegafur-uracil plus leucovorin versus capecitabine. Clin Colorectal Cancer. 2017;16:e141–e5.CrossRef

Tsuchiya T, Sadahiro S, Sasaki K, Kondo K, Katsumata K, Nishimura G, et al. Safety analysis of two different regimens of uracil-tegafur plus leucovorin as adjuvant chemotherapy for high-risk stage II and III colon cancer in a phase III trial comparing 6 with 18 months of treatment: JFMC33-0502 trial. Cancer Chemother Pharmacol. 2014;73:1253–61.CrossRef

Shirao K, Hoff PM, Ohtsu A, Loehrer PJ, Hyodo I, Wadler S, et al. Comparison of the efficacy, toxicity, and pharmacokinetics of a uracil/tegafur (UFT) plus oral leucovorin (LV) regimen between Japanese and American patients with advanced colorectal cancer: joint United States and Japan study of UFT/LV. J Clin Oncol. 2004;22:3466–74.CrossRef

Brierley J, Gospodarowicz M, Wittekind CTNM. Classification of malignant tumours. 8th ed: Wiley-Blackwell; 2016.

Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL, et al. A model to predict survival in patients with end-stage liver disease. Hepatology. 2001;33:464–70.CrossRef

10.

Toide H, Akiyoshi H, Minato Y, Okuda H, Fujii S. Comparative studies on the metabolism of 2-(tetrahydrofuryl)-5-fluorouracil and 5-fluorouracil. Gan. 1977;68:553–60.PubMed

11.

Gonzalez-Baron M, Feliu J, de la Gandara I, Espinosa E, Colmenarejo A, Martinez-Martinez B, et al. Efficacy of oral tegafur modulation by uracil and leucovorin in advanced colorectal cancer. A phase II study. Eur J Cancer. 1995;31A:2215–9.CrossRef

12.

Shimada Y, Hamaguchi T, Mizusawa J, Saito N, Kanemitsu Y, Takiguchi N, et al. Randomised phase III trial of adjuvant chemotherapy with oral uracil and tegafur plus leucovorin versus intravenous fluorouracil and levofolinate in patients with stage III colorectal cancer who have undergone Japanese D2/D3 lymph node dissection: final results of JCOG0205. Eur J Cancer. 2014;50:2231–40.CrossRef

13.

Lembersky BC, Wieand HS, Petrelli NJ, O’Connell MJ, Colangelo LH, Smith RE, et al. Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06. J Clin Oncol. 2006;24:2059–64.CrossRef

14.

Chalasani NP, Hayashi PH, Bonkovsky HL, Navarro VJ, Lee WM, Fontana RJ, et al. ACG clinical guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. Am J Gastroenterol. 2014;109:950–66 quiz 67.CrossRef

15.

Danan G, Teschke R. RUCAM in drug and herb induced liver injury: the update. Int J Mol Sci. 2015;17.CrossRef

16.

Institute NC. Common terminology criteria for adverse events (CTCAE) version 5.0. In.

17.

Baba M, Shima T, Tanaka T, Nakayabu M, Hasegawa H, Suzuki S, et al. A case of allergic liver injury induced by tegafur. J Gastroenterol. 1994;29:88–92.CrossRef

18.

Kobayashi F, Ikeda T, Sakamoto N, Kurosaki M, Tozuka S, Sakamoto S, et al. Severe chronic active hepatitis induced by UFTR containing tegafur and uracil. Dig Dis Sci. 1995;40:2434–7.CrossRef

19.

Maruyama S, Hirayama C, Abe J, Tanaka J, Matsui K. Chronic active hepatitis and liver cirrhosis in association with combined tamoxifen/tegafur adjuvant therapy. Dig Dis Sci. 1995;40:2602–7.CrossRef

20.

Matsumoto M, Nakao K, Matsumoto H, Iwata K, Ohta Y, Kanai K, et al. Chronic liver failure induced by long-term administration of tegafur: a case report. Hepatogastroenterology. 1998;45:2372–5.PubMed

21.

Akiyama T, Hayashi H, Matsuyama T, Nomura A. Severe multiple organ damage by uracil-tegafur in stage IB lung cancer. Cancer Science: Open Access. 2017;3.

22.

Reuben A, Koch DG, Lee WM, Acute Liver Failure Study G. Drug-induced acute liver failure: results of a U.S. multicenter, prospective study. Hepatology. 2010;52:2065–76.CrossRef

23.

Lee WM. Drug-induced acute liver failure. Clin Liver Dis. 2013;17:575–86 viii.CrossRef

Title: An Unusual Case of Acute Liver Failure Caused by Adjuvant Oral Tegafur-Uracil with Folinate Therapy for Colon Cancer Patient: a Case Report
Authors: Masatsugu Hiraki
Toshiya Tanaka
Futa Koga
Akimasa Saito
Noriko Oza
Osamu Ikeda
Tatsuya Manabe
Atsushi Miyoshi
Kenji Kitahara
Seiji Sato
Hirokazu Noshiro
Publication date: 01-03-2020
Publisher: Springer US
Keywords: Acute Liver Failure
Colon Cancer
Colon Cancer
Published in: Journal of Gastrointestinal Cancer / Issue 1/2020
Print ISSN: 1941-6628
Electronic ISSN: 1941-6636
DOI: https://doi.org/10.1007/s12029-019-00228-7

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2020

Locally Advanced Rectal Cancer Evaluation by Magnetic Resonance Imaging after Neoadjuvant Therapy on Decision Making: Cancer Center Experience and Literature Review

Pulsatile Bony Secondaries from a GI Malignancy: an Unknown Entity!

Pancreatic Malignant Gastrointestinal Stromal Tumor: a Case Report

Surgical Management of Bleeding Duodenal Stromal Tumours with Shock

Computerized Tomography Criteria as a Tool for Simplifying the Assessment of Locally Advanced Rectal Cancer

Gastrointestinal Mantle Cell Lymphoma with Varied Findings

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials